Skip to main content
OpenTrials
Completed

NCT Number: NCT00795561

Management of Nausea and Vomiting of Pregnancy

Upto 80% of all pregnant women experience some form of nausea and vomiting (NVP) during their pregnancy. Hyperemesis gravidarum, a more severe form of NVP affects approximately 0.3- 2.0% of pregnancies and is the commonest indication for admission to hospital in the first half of pregnancy and second only to preterm labor as a cause of hospitalization overall. According to the Hyperemesis Education and Research Foundation, conservative estimates indicate that HG can cost a minimum of $200 million annually in house hospitalizations in the United States of America. The investigators aim to conduct a randomized controlled trial to test the hypothesis that the availability of day care services for the initial treatment of NVP reduces the mean duration of stay in hospital by 1 day and results in significantly greater patient satisfaction compared with standard inpatient management.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Department of Obstetrics and Gynaecology, Cork University Maternity Hospital

Cork, Ireland

About this study

Upto 80% of all pregnant women experience some form of nausea and vomiting during their pregnancy (NVP). The International Statistical Classification of Disease and Related Health Problems ICD-10 defines hyperemesis gravidarum (HG) as persistent and excessive vomiting starting before the end of the 22nd week of gestation, and further subdivides the condition into mild and severe, severe being associated with metabolic disturbances such as carbohydrate depletion, dehydration or electrolyte imbalance. HG is a diagnosis of exclusion, characterized by prolonged and severe nausea and vomiting, dehydration, large ketonuria and > 5% bodyweight loss.

HG affects approximately 0.3- 2.0% of pregnancies and is the commonest indication for admission to hospital in the first half of pregnancy and second only to preterm labor as a cause of hospitalisation overall. According to the Hyperemesis Education and Research Foundation, conservative estimates indicate that HG can cost a minimum of $200 million annually in house hospitalizations in the United states. Taking into account other factors such as emergency room treatments, potential complications of severe HG and the fact that up to 35% of women with paid employment will lose time from work through nausea the actual cost of NVP to the economy is significantly higher.

NVP can be extremely debilitating for the patient and if inadequately managed can cause significant morbidities including malnutrition and electrolyte imbalances, thrombosis, Wernicke's encephalopathy, depressive illness and poor pregnancy outcomes such as prematurity and small for gestational age fetuses.

Day care has proven to be beneficial and safe mode of care for patients in other clinical settings. Studies have demonstrated that day care management of patients with NVP appears acceptable and feasible but no systematic reviews or randomized controlled trials have been performed which examine the effects of introducing day care on rates of hospital admission, duration of inpatient stay and patient satisfaction.

We aim to conduct a prospective open label randomized controlled trial to test the hypothesis that the availability of day care services for the initial treatment of NVP reduces the mean duration of stay in hospital by 1 day (28.6%) and results in significantly greater patient satisfaction compared with standard inpatient management.

The null hypothesis states there is no difference in the amount of inpatient hospital days when women with NVP are treated initially in day care or by standard inpatient admission.

All pregnant women under 22 weeks gestation, who have not already been treated for NVP in their current pregnancy, presenting with the diagnosis of NVP are eligible for inclusion in the trial. The treatment group will be day care treatment of NVP. The comparison group will be the inpatient treatment of NVP.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women (no age limits) will be admitted to the study if they have two or more of the following criteria

  • Ongoing viable intrauterine pregnancy/ pregnancies < 22 weeks gestation
  • Persistent vomiting (>x3 episodes/ 24 hours) not attributable to other causes
  • Severe nausea not attributable to other causes.
  • Dehydration diagnosed by the presence of ketonuria.
  • Electrolyte imbalance not attributable to other causes.

Exclusion criteria

Women will not be admitted to the study if any of the following criteria are present.

  • Women with a confirmed urinary tract infection (mid stream urine isolation of a single strain of uropathogen >105 bacteria/ml)
  • Women with molar pregnancies
  • Women with non viable pregnancies.
  • Women who have already received treatment for NVP outside of this trial.
  • Pregnant women who present who will not be booking at CUMH for their pregnancy or are not resident in the South West of Ireland i.e. day care treatment is not an option.
  • Women who do not have a good understanding of English.

Treatment and study plan

Day care

Procedure

Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.

Other names: day unit, day services

Inpatient

Procedure

Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.

Other names: admission

Primary outcomes

  1. The primary outcome will be the number of inpatient nights spent in hospital secondary to NVP from initial presentation until 22 weeks gestation. An inpatient night will be defined as requiring an inpatient bed between the hours of 20.00 and 08.00.

    Time frame: Following discharge

Secondary outcomes

  1. Total number of hours spent in hospital secondary to NVP from initial presentation until 22 weeks gestation.

    Time frame: 22 weeks gestation

  2. Total amount of intravenous fluids administered secondary to NVP from initial presentation until 22 weeks gestation

    Time frame: 22 weeks gestation

  3. Total amount of anti-emetics administered secondary to NVP from initial presentation until 22 weeks gestation.

    Time frame: 22 weeks gestation

  4. Total Multivitamin complexes administered secondary to NVP from initial presentation until 22 weeks gestation

    Time frame: 22 weeks gestation

  5. Patient satisfaction will be measured by the Client Satisfaction Questionnaire.

    Time frame: Following first presentation

  6. Incidence of miscarriage

    Time frame: 22 weeks gestation

  7. Infant birth weight at delivery

    Time frame: Following delivery

  8. Gestational age at delivery.

    Time frame: following delivery

  9. Total days lost at work secondary to NVP from initial presentation until 22 weeks gestation. (Asked at 16 weeks gestation)

    Time frame: 16 weeks gestation

Sponsors and collaborators

Lead sponsor

University College Cork

Other

Registry information

Official study title

Randomized Controlled Trial of Day Care Versus Inpatient Management of Nausea and Vomiting of Pregnancy

Acronym: DIM

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Nov 21, 2008
Registry last updated
Jan 15, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.